Data investigation

FDA Warning Letters to Compounded GLP-1 Telehealth Providers: The Live Investigation

Every FDA warning letter we have identified that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business — with violation patterns, issuing offices, and what is actually being cited. Live dataset, updated bi-weekly via automated FDA scraper.

By the Weight Loss Rankings editorial team·10 min read·120 citations·Published 2026-04-06·Updated 2026-03-31
  • FDA enforcement
  • Compounded GLP-1
  • Live dataset

Weight Loss Rankings maintains a continuously-updated database of every FDA warning letter we've been able to identify that targets a compounded GLP-1 telehealth provider, compounding pharmacy, or related weight-loss business. As of March 31, 2026, the database contains 120 letters spanning from October 2, 2023 to March 31, 2026. This investigation breaks down what FDA is actually citing — the violation categories, issuing offices, and the patterns that should make a prospective patient cautious about specific business models.

What FDA is citing, by subject category

Every letter in our database carries a verbatim subject line from the FDA letter itself. Grouping by subject reveals what the agency is actually concerned about right now.

Subject categoryLettersShare
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet4941%
False & Misleading Claims/Misbranded3428%
Compounded GLP-1 marketing and labeling concerns1714%
Compounding Pharmacy/Adulterated Drug Products65%
Unapproved New Drugs/Misbranded54%
Unapproved New Drugs Sold Over the Internet43%
CGMP/Finished Pharmaceuticals/Adulterated22%
Postmarketing Adverse Drug Experience Reporting Requirements11%
Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet11%
Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded11%

The dominant pattern is clear: 115 of 120 letters in the database (96%) target marketing, labeling, or compounding-quality issues at compounded GLP-1 telehealth businesses. Only 5 letters in the dataset address other concerns.

Issuing offices

Where the letter comes from inside FDA matters. Letters from the Center for Drug Evaluation and Research (CDER) are typically the result of an internet sweep — FDA staff find a website making questionable claims, and the violation letter follows. Letters from district field offices usually follow an in-person inspection of a compounding pharmacy.

Issuing officeLetters
Center for Drug Evaluation and Research (CDER)118
Center for Drug Evaluation and Research | CDER2

Every letter in our database

Each entry below links to our editorial summary plus a verbatim excerpt of what FDA cited. We add new letters within two weeks of FDA publication via an automated discovery and review process.

The patterns that should make you cautious

Reading every letter in the database reveals three recurring red flags worth knowing about as a patient:

  1. Branded compounded products. Several letters cite telehealth providers for putting their own brand name on the vial label of a compounded drug, suggesting to consumers that the compounded product was manufactured by the telehealth company itself. FDA considers this misbranding because the actual compounder is a third-party 503A pharmacy that the patient never sees.
  2. Implied FDA approval. Multiple letters cite marketing language that uses words like “safe,” “FDA-approved,” or “FDA-registered” in contexts that misrepresent the regulatory status of compounded drugs. Compounded semaglutide is not FDA-approved, no matter how the website phrases it.
  3. Adulteration findings on inspection. The letters from district field offices (rather than CDER) typically follow an in-person inspection that found cGMP violations — sterility failures, environmental monitoring lapses, or use of bulk drug substances that aren't eligible under the 503A or 503B exemptions. These are the most serious letters in the database.

How to use this database as a patient

Before you start a compounded GLP-1 program, search this database for the telehealth provider you're considering AND the compounding pharmacy they list as their fulfillment partner. A warning letter doesn't automatically mean the company is unsafe — many companies remediate the cited violations and continue operating — but it tells you what to ask about during your consultation.

Specific questions to ask any compounded GLP-1 provider:

  • Has your company or your fulfillment pharmacy received any FDA warning letters? If yes, what was cited and what changed?
  • Is your pharmacy registered with FDA as a 503B outsourcing facility? If not, which state board of pharmacy licenses them?
  • What is the exact form of semaglutide or tirzepatide in your product — base molecule, sodium salt, or acetate salt? FDA has warned that salt forms are not the same active ingredient as the base molecule used in approved drugs.

Methodology

Our FDA letter database is updated bi-weekly via an automated scraper that pulls from FDA's public warning letters index. Every letter we add is verified against the original FDA publication URL, with violation summaries quoted verbatim from the FDA letter text. We never paraphrase a violation. The full methodology is documented in our editorial standards.

Our pricing index, pharmacy database, and the rest of the WLR editorial dataset is documented at our master sources page. The underlying FDA letter records are in our public repository.

Related research

For the regulatory and market context this enforcement database fits into: